18F-FDG, as a single imaging agent in assessing cancer, shows the ongoing biological phenomena in many domains: do we need additional tracers for clinical purposes?

Nucl Med Commun. 2016 Apr;37(4):333-7. doi: 10.1097/MNM.0000000000000478.

¹ aDepartment of Radiology and Nuclear Medicine, University Medical Center Utrecht, Utrecht, The Netherlands bDepartment of Radiology, Hospital of the University of Pennsylvania, Philadelphia, Pennsylvania, USA cDepartment of Nuclear Medicine, PET/CT Centre, Radiology, Interventional Radiology NeuroRadiology, Medical Physics, Clinical Laboratory, Biomarkers Laboratory, Pathology, Microbiology, 'Santa Maria della Misericordia' Hospital, Rovigo, Italy dDepartment of Nuclear Medicine, Odense University Hospital eInstitute of Clinical Research, University of Southern Denmark, Odense, Denmark.

No abstract available

Publication types